Skip to main content
. 2019 Sep 25;5(9):eaaw6499. doi: 10.1126/sciadv.aaw6499

Fig. 3. Tumor transfection in vivo and inhibition of tumor growth by HNTs/siRIPK4.

Fig. 3

(A) In vivo imaging of T24 xenograft–bearing mice after intratumoral injection of HNTs/FAM-siRIPK4, free FAM-siRIPK4, HNTs, or PBS (n = 3 mice in each group). (B) In vivo imaging of T24 xenograft–bearing mice after tail vein injection of HNTs/FAM-siRIPK4, free FAM-siRIPK4, HNTs, or PBS (n = 3 mice in each group). (C) Timeline for the assessment of the antitumor activities of the HNTs/siRIPK4 complexes in the in vivo subcutaneous xenograft model. (D) Images of the tumors dissected from tumor-bearing mice receiving various treatments (n = 5 mice in each group). (E) Relative tumor volume in BALB/c nude mice with HNTs/siRIPK4 xenografts over time. (F) Weight of tumors dissected from mice after treatment. ***P < 0.001.